James J Vredenburgh
Overview
Explore the profile of James J Vredenburgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
5534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sklavenitis-Pistofidis R, Aranha M, Redd R, Baginska J, Haradhvala N, Hallisey M, et al.
Cancer Cell
. 2022 Nov;
40(11):1358-1373.e8.
PMID: 36379208
Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes. We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients...
2.
Ozcan G, Singh M, Vredenburgh J
Clin Cancer Res
. 2022 Aug;
29(1):11-29.
PMID: 35972437
Leptomeningeal metastasis (LM), also known as leptomeningeal carcinomatosis (LC), is a devastating complication of metastatic cancer that occurs when neoplastic cells invade the meningeal space. Diagnosis of LM remains challenging...
3.
Reardon D, Desjardins A, Vredenburgh J, ORourke D, Tran D, Fink K, et al.
Clin Cancer Res
. 2020 Feb;
26(7):1586-1594.
PMID: 32034072
Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed,...
4.
Mathew Thomas V, Bindal P, Vredenburgh J
Case Rep Oncol
. 2019 May;
12(1):126-130.
PMID: 31043950
Meningiomas are primary CNS tumors that arise from the arachnoid layer of the meninges. Genomic sequencing has revealed that NF2 mutations are the most common genetic alteration seen in meningiomas....
5.
Rao V, Bauer F, Vredenburgh J
Conn Med
. 2018 May;
80(7):409-412.
PMID: 29782128
Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis (HNL), is a rare, self-limiting disease most commonly reported in young Asian women worldwide. We present the case of a 27-year-old...
6.
Rao V, Bauer F, Vredenburgh J
Conn Med
. 2018 May;
80(9):529-532.
PMID: 29772136
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare yet highly aggressive malignancy with a poor prognosis. Currently, there are no SCCOHT treatment guidelines. After surgery, many...
7.
Affronti M, Woodring S, Peters K, Herndon 2nd J, McSherry F, Healy P, et al.
Ther Clin Risk Manag
. 2017 Jan;
13:33-40.
PMID: 28096679
Purpose: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority...
8.
Affronti M, Woodring S, Allen K, Kirkpatrick J, Peters K, Herndon 2nd J, et al.
Support Care Cancer
. 2016 Jun;
24(10):4365-75.
PMID: 27271867
Background: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially...
9.
Strowd 3rd R, Rodriguez F, McLendon R, Vredenburgh J, Chance A, Jallo G, et al.
Am J Med Genet A
. 2016 Mar;
170(6):1455-61.
PMID: 26992069
Although optic pathway gliomas are the most common brain tumors associated with neurofibromatosis type 1 (NF1), extra-optic gliomas occur and may behave more aggressively with outcomes that differ by age....
10.
Mar N, Vredenburgh J
Conn Med
. 2015 Dec;
79(9):531-5.
PMID: 26630704
Identification of targetable oncogenic mutations in non-small cell lung cancer (NSCLC) has been a major advance in cancer treatment. Laboratory techniques to assess human epidermal growth factor receptor 2 (HER2)...